Brokerages Set Trevi Therapeutics, Inc. (NASDAQ:TRVI) Price Target at $21.75

Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) have been assigned an average rating of “Moderate Buy” from the nine analysts that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, seven have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $21.75.

Several brokerages recently commented on TRVI. Raymond James Financial cut their price target on shares of Trevi Therapeutics from $29.00 to $27.00 and set a “strong-buy” rating for the company in a research note on Friday, August 8th. Needham & Company LLC cut their price target on shares of Trevi Therapeutics from $24.00 to $22.00 and set a “buy” rating for the company in a research note on Friday, August 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Trevi Therapeutics in a research note on Wednesday, October 8th. Finally, Morgan Stanley assumed coverage on shares of Trevi Therapeutics in a research note on Thursday, August 21st. They issued an “overweight” rating and a $18.00 price target for the company.

Trevi Therapeutics Price Performance

Shares of NASDAQ TRVI opened at $11.66 on Wednesday. The firm has a market capitalization of $1.42 billion, a P/E ratio of -27.76 and a beta of 0.74. The company’s 50 day simple moving average is $9.11 and its 200 day simple moving average is $7.48. Trevi Therapeutics has a fifty-two week low of $2.36 and a fifty-two week high of $11.68.

Trevi Therapeutics (NASDAQ:TRVI) last issued its earnings results on Thursday, August 7th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.01. Sell-side analysts expect that Trevi Therapeutics will post -0.49 EPS for the current fiscal year.

Institutional Trading of Trevi Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Russell Investments Group Ltd. increased its holdings in Trevi Therapeutics by 194.5% in the 2nd quarter. Russell Investments Group Ltd. now owns 4,536 shares of the company’s stock valued at $25,000 after buying an additional 2,996 shares during the period. Strs Ohio bought a new stake in shares of Trevi Therapeutics during the 1st quarter valued at approximately $52,000. Farther Finance Advisors LLC grew its holdings in shares of Trevi Therapeutics by 15,969.1% during the 2nd quarter. Farther Finance Advisors LLC now owns 8,838 shares of the company’s stock valued at $48,000 after purchasing an additional 8,783 shares during the last quarter. Catalyst Funds Management Pty Ltd bought a new stake in shares of Trevi Therapeutics during the 2nd quarter valued at approximately $56,000. Finally, Rafferty Asset Management LLC bought a new stake in shares of Trevi Therapeutics during the 2nd quarter valued at approximately $60,000. Institutional investors and hedge funds own 95.76% of the company’s stock.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.